• SENSEX
    NIFTY 50
Market

Wednesday's top brokerage calls: NMDC, Mindtree and more

Updated : July 14, 2021 09:05 AM IST

Among brokerages, JPMorgan and Citi are 'neutral' on NMDC after the company’s board approved the demerger of the steel plant. Meanwhile, Goldman Sachs and Morgan Stanley are bullish on Mindtree after its June quarter earnings. Here's a look at the top brokerage calls for today:

 JPMorgan on NMDC : The brokerage is 'neutral' on the stock with the target at Rs 210 per share. It said that the start of the firm's steel plant demerger is positive as it limits liability to the firm from steel plant losses.
JPMorgan on NMDC: The brokerage is 'neutral' on the stock with the target at Rs 210 per share. It said that the start of the firm's steel plant demerger is positive as it limits liability to the firm from steel plant losses.
 Citi on NMDC:  The brokerage is 'neutral' on the stock with the target at Rs 195 per share after the company’s board approved the demerger of the steel plant. It says demerger could help unlock value for the iron ore business.
Citi on NMDC: The brokerage is 'neutral' on the stock with the target at Rs 195 per share after the company’s board approved the demerger of the steel plant. It says demerger could help unlock value for the iron ore business.
 Goldman Sachs on Mindtree:  The brokerage has a 'buy' call on the stock with the target at Rs 2,863 per share. It expects 20.5 percent constant currency revenue growth for the firm in FY22.
Goldman Sachs on Mindtree: The brokerage has a 'buy' call on the stock with the target at Rs 2,863 per share. It expects 20.5 percent constant currency revenue growth for the firm in FY22.
 Morgan Stanley on Mindtree:  The brokerage is 'overweight' on the stock with the target at Rs 2,800 per share. It said that high multiples and limited EPS estimate upgrades limit absolute upside.
Morgan Stanley on Mindtree: The brokerage is 'overweight' on the stock with the target at Rs 2,800 per share. It said that high multiples and limited EPS estimate upgrades limit absolute upside.
 Citi on Mindtree:  The brokerage has a 'sell' call on the stock with the target at Rs 2,215 per share. It noted that valuations appear rich at current levels and that client concentration and risk to margins are key.
Citi on Mindtree: The brokerage has a 'sell' call on the stock with the target at Rs 2,215 per share. It noted that valuations appear rich at current levels and that client concentration and risk to margins are key.
 Credit Suisse on Aurobindo Pharma:  The brokerage maintains an 'outperform' call on the stock with the target at Rs 1,230 per share. High growth in FY24 reflects benefits of multiple growth drivers, said the brokerage.
Credit Suisse on Aurobindo Pharma: The brokerage maintains an 'outperform' call on the stock with the target at Rs 1,230 per share. High growth in FY24 reflects benefits of multiple growth drivers, said the brokerage.
Published : July 14, 2021 09:05 AM IST
Live TV

recommended for you

Ask Our Experts CNBC TV18

Advertisement